In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, GSK Plc ADR (NYSE: GSK) closed at $38.64 down -2.72% from its previous closing price of $39.72. In other words, the price has decreased by -$2.72 from its previous closing price. On the day, 8.17 million shares were traded. GSK stock price reached its highest trading level at $39.52 during the session, while it also had its lowest trading level at $38.58.
Ratios:
For a deeper understanding of GSK Plc ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.36. For the most recent quarter (mrq), Quick Ratio is recorded 0.58 and its Current Ratio is at 0.87. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.16.
On April 15, 2025, Exane BNP Paribas started tracking the stock assigning a Neutral rating and target price of $35.25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 27 ’24 when GSK plc bought 2,791,930 shares for $8.00 per share. The transaction valued at 22,335,440 led to the insider holds 16,775,691 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GSK now has a Market Capitalization of 81307058176 and an Enterprise Value of 171261919232. As of this moment, GSK’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.06, and their Forward P/E ratio for the next fiscal year is 7.83. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.04. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95 while its Price-to-Book (P/B) ratio in mrq is 4.32. Its current Enterprise Value per Revenue stands at 5.432 whereas that against EBITDA is 19.79.
Stock Price History:
The Beta on a monthly basis for GSK is 0.52, which has changed by -0.052011788 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, GSK has reached a high of $44.67, while it has fallen to a 52-week low of $31.72. The 50-Day Moving Average of the stock is 0.92%, while the 200-Day Moving Average is calculated to be 3.14%.
Shares Statistics:
For the past three months, GSK has traded an average of 5.33M shares per day and 4870210 over the past ten days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.00% of the company’s shares, while institutions hold 18.11% stake in the company. Shares short for GSK as of 1748563200 were 16670244 with a Short Ratio of 3.13, compared to 1745971200 on 17365710. Therefore, it implies a Short% of Shares Outstanding of 16670244 and a Short% of Float of 0.8200000000000001.
Dividends & Splits
According to the company, the forward annual dividend rate for GSK is 1.61, from 0.62 in the trailing year. Against a Trailing Annual Dividend Yield of 0.015609264The stock’s 5-year Average Dividend Yield is 4.77. The current Payout Ratio is 94.89% for GSK, which recently paid a dividend on 2025-05-16 with an ex-dividend date of 1747353600. Stock splits for the company last occurred on 2022-07-22 when the company split stock in a 1226:1000 ratio.
Earnings Estimates
The market rating for GSK Plc ADR (GSK) is a result of the insights provided by 2.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $1.34, with high estimates of $1.41 and low estimates of $1.28.
Analysts are recommending an EPS of between $4.56 and $4.16 for the fiscal current year, implying an average EPS of $4.36. EPS for the following year is $4.86, with 5.0 analysts recommending between $5.08 and $4.48.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $7.92B this quarter.It ranges from a high estimate of $8.29B to a low estimate of $7.72B. As of the current estimate, GSK Plc ADR’s year-ago sales were $7.88BFor the next quarter, 6 analysts are estimating revenue of $8.23B. There is a high estimate of $8.37B for the next quarter, whereas the lowest estimate is $8.02B.
A total of 18 analysts have provided revenue estimates for GSK’s current fiscal year. The highest revenue estimate was $32.98B, while the lowest revenue estimate was $31.5B, resulting in an average revenue estimate of $32.24B. In the same quarter a year ago, actual revenue was $31.38BBased on 19 analysts’ estimates, the company’s revenue will be $34.06B in the next fiscal year. The high estimate is $35.86B and the low estimate is $32.84B.
